How many investments has Rock Springs Capital made?

Rock Springs Capital has 29 tracked investments, 8 of which have exited, including 3 dated in the last 24 months.

What stage does Rock Springs Capital invest at?

Rock Springs Capital invests at the Late Stage stage.

What sectors does Rock Springs Capital focus on?

Rock Springs Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is Rock Springs Capital located?

Rock Springs Capital is headquartered in Baltimore, US.

Rock Springs Capital

Venture capital

Baltimore · Late Stage · 13 people tracked

Also known as ROCK SPRINGS CAPITAL MANAGEMENT LP

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Rock Springs Capital

632 people in our graph share verified history with the Rock Springs Capital team — schools, employers, funds. One of them is your warm intro.

Sethunlockedknows Mark Bussard · together at T. Rowe Price (overlapped)

×8knows the team · via T. Rowe Price

×3knows the team · via Loyola University Maryland

✨ Fox Verdict

Investment thesis

Rock Springs Capital pursues research-driven investing across healthcare sectors, combining deep scientific and clinical insight with a rigorous, fundamental approach. Founded by physician-scientists, the firm brings together sector specialists whose senior team has collaborated for over two decades. Its methodology leverages the full resources of the firm to identify healthcare innovations believed to be positioned for long-term value, emphasizing companies that address critical unmet medical needs. The firm stresses experience, continuity, shared investment discipline, and a reputation for integrity.

Invests inBiotech Digital Health Healthtech Medical Devices Baltimore United States

Source: firm website, verified Sep 22, 2026.

Stage

Late Stage

Baltimore, US

Instruments

Equity

Founded

2013

Last 12 months

1 investment

AUM

$2.4B

Tracked investments

IPOs

Team · 13 people

from the firm's website & public directories

Kris Jenner· Co-Founder· Annapolis, Maryland, United Statesin

Physician (MD, D.Phil.) who co-founded Rock Springs Capital, bringing deep scientific and clinical expertise to the firm's healthcare investing.

Mark Bussard· Co-Founder· Reisterstown, Maryland, United Statesin

Physician (MD) who co-founded Rock Springs Capital, contributing clinical and scientific insight to the firm's investment approach.

Scott Schafer· Partner· Fallston, Maryland, United Statesin

Joined Rock Springs at inception after ten years as a research associate at T. Rowe Price covering medical device, biotech and healthcare companies. Holds a B.S. from Salisbury University, an M.B.A. from Loyola University, and the CFA designation.

Aidan O'Connor· General Counsel & Chief Compliance Officer

Leads legal and compliance; previously Chief Regulatory Counsel and CCO (U.S.) at SoftBank Investment Advisers, Senior Counsel at the SEC, and an attorney at Skadden. Holds a J.D. from Georgetown.

Allison Wald· Analyst

Joined Rock Springs in 2025 after completing a Ph.D. in Biomedical Engineering at Johns Hopkins, where she interned at Johns Hopkins Technology Ventures. Also earned an M.S. from Johns Hopkins and a B.S. from the University of Virginia.

Dan Lundgren· Analyst

Joined Rock Springs in 2021; previously worked in business development at Cabaletta Bio through its Series A, B and IPO, and did graduate research at the NIH. Earned a B.S. in Economics from Wharton and a B.A. in Biology from UPenn.

Matt Rosenberg· Analyst

Joined Rock Springs in 2024 after founding and selling a cloud-based practice management solution and advising healthcare clients at McKinsey. Holds an A.B. from Harvard and an M.D. from Yale.

Michael Patti· Director of Investor Relations· Cambridge, Massachusetts, United Statesin

Leads investor relations; previously Director of Business Development at Select Equity Group and held sales roles at Schroders, BNY Mellon, and Fidelity. Holds a B.S. from Boston University.

Nnamdi Etoh· Chief Financial Officer· Baltimore, Maryland, United Statesin

Joined Rock Springs in 2016 after serving as VP of Finance at Grand Brands and a corporate tax accountant at T. Rowe Price. Holds a B.A. from Duke and the CPA and CMA designations.

Taylor Beccone· Controller· Baltimore, Maryland, United Statesin

Joined Rock Springs in 2019 after roles as an assistant controller at Greenspring Associates and an audit associate at CohnReznick. Holds a B.S. in Accounting from Mount St. Mary's University and the CPA designation.

Temi Akande· Analyst

Joined Rock Springs in 2024 after working as an investment analyst at Alyeska Investment Group covering MedTech and healthcare services. Holds a B.S. from Oklahoma State, an M.B.A. from Wharton, and an M.P.A. from Harvard Kennedy School; formerly an aerospace engineer at American Airlines.

Veric Tan· Analyst· Baltimore, Maryland, United Statesin

Joined Rock Springs in 2024; earned B.S. degrees in Materials Science and Cognitive Science from Johns Hopkins and previously served as a lieutenant in the Singapore Armed Forces.

Gordon Margraff (Mark) Bussard· Executive Officer

What they invest in

from 29 of 29 portfolio companies

Biotech ×24Healthtech ×14Medical Devices ×6AI & Machine Learning ×3Enterprise Software ×2SaaS ×2Advanced Manufacturing ×1Climate Tech ×1

HQs:United States×18United Kingdom×2Germany×1Vietnam×1

Investments · 33 tracked

founders shown can be your intro path

By year:2026 · 1 2025 · 1 2024 · 2 2023 · 2 2022 · 2 2021 · 4 2020 · 2 2019 · 4 2017 · 119 dated

Avalyn Pharma Incavalynpharma.com inNASDAQ: AVLNSep 2023 · $175M

Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.

BiotechHealthtech

Lyn Baranowski(CEO)in

Co-investorsAndera Partners Catalio Capital Management, LP F-Prime Capital InVivium Capital Norwest Venture Partners Pivotal Life Sciences +9 more

Bolt Biotherapeuticsboltbio.com in 𝕏NASDAQ: BOLT

Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.

BiotechHealthtechMedical DevicesSan Francisco, US

Dr. Edgar G. Engleman(Founder)

Co-investorsPfizer Venture Investments Pivotal Life Sciences RA Capital Samsara BioCapital Sofinnova Ventures Vivo Capital +3 more

Disc Medicinediscmedicine.com in 𝕏NASDAQ: IRONSep 2021 · $90M

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

John Quisel(Chief Executive Officer)in Jean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)in Pamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in

Co-investorsAccess Biotechnology Atlas Venture Bain Capital Life Sciences Foresite Capital Frazier Life Sciences OrbiMed +6 more

ImaraNASDAQ: ELVNMar 2019 · $63Macquired by Enliven Therapeutics · Feb 2023

Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.

BiotechCambridge, US

James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)

BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)

Co-investorsBay City Capital New Enterprise Associates (NEA)RA Capital Alexandria Arix Bioscience Lundbeckfonden Ventures +2 more

Immuneeringimmuneering.com in 𝕏NASDAQ: IMRX

Immuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects.

BiotechHealthtechCambridge, US

Benjamin J. Zeskind(Executive Officer, Director)Harold E. Brakewood(Chief Business Officer)in Brett Hall(Chief Scientific Officer)inMichael D. Bookman(Chief Legal Officer, Secretary)inIgor Matushansky(Chief Medical Officer)Mallory Morales(SVP Finance, Chief Accounting Officer, Treasurer)in

Co-investorsT. Rowe Price

Korro Biokorrobio.com in 𝕏NASDAQ: KRROApr 2024 · $70M

Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology.

BiotechHealthtechCambridge, US

Nessan Bermingham(Mr. Bermingham is the Executive Chair of the Issuer.)in Jean-François Formela(Director)in Ommer Chohan(Mr. Chohan is the Secretary and Treasurer of the Issuer.)in Ram Aiyar(Chief Executive Officer, President and Director)in Todd Chappell(Chief Operating Officer)in

Board Jean-Francois Formela(Director)in

Co-investorsAtlas Venture MC Healthcare Ventures New Enterprise Associates (NEA)Alexandria Qiming Venture Partners USA Taiwania Capital +1 more

Xilio Therapeuticsxiliotx.com inNASDAQ: XLO

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)in Katarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)

Co-investorsBain Capital Life Sciences Bay City Capital F-Prime Capital M Ventures MRL Ventures Fund RA Capital +9 more

Apollo Therapeuticsapollotherapeutics.com in✓ verified

A portfolio biopharmaceutical company that translates breakthroughs in biology and basic medical research from top universities into novel therapeutics.

BiotechHealthtechCambridge, GB

Co-investorsPatient Square Capital AlbionVC UCL Technology Fund

Apollo Therapeuticsapollotx.com inSep 2023 · $226.5M✓ verified

A portfolio biopharmaceutical company translating basic medical research breakthroughs from leading universities into novel therapeutic medicines.

BiotechDeep TechMedical DevicesCambridge, GB

Richard Butt(Chief Scientific Officer)in Sanjay Aggarwal(Chief Medical Officer)in

Co-investorsPatient Square Capital AlbionVC

Abcuroabcuro.comAug 2026

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)

Co-investorsBain Capital Life Sciences New Enterprise Associates (NEA)RA Capital Samsara BioCapital Sanofi Ventures Mass General Brigham Ventures +9 more

Affinivaxaffinivax.com in 𝕏

Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology.

BiotechMedical DevicesCambridge, US

Richard Malley(Director)inKamran Tavangar(Executive Officer)Steven Brugger(Executive Officer, Director)in

BoardRobert More(Director)Frances Heller(Director)George Siber(Director)

Co-investorsBain Capital Life Sciences EcoR1 Capital Foresite Capital Bain Capital T. Rowe Price

Aptinyxaptinyx.com

BiotechEvanston, US

Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)

BoardLiam Ratcliffe(Director)Terry P. Gould(Director)

Co-investorsBain Capital Life Sciences Frazier Life Sciences Latterell Venture Partners Longitude Capital OUP (Osage University Partners)Agent Capital +3 more

Arsenal Biosciencesarsenalbio.comSep 2024

Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors.

BiotechHealthtechMedical DevicesSouth San Francisco, US

Ken Drazan(Founder)James Ahlers(Executive Officer)Irene Pleasure(Executive Officer)Margaret Nibbi(Executive Officer)

BoardValentin Barsan(Director)Sean Parker(Director)

Co-investorsARCH Venture Partners Hitachi Ventures Kleiner Perkins OUP (Osage University Partners)SoftBank Vision Fund Westlake Village BioPartners +2 more

City Therapeuticscitytx.com in 𝕏Oct 2024

City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.

BiotechMedical DevicesCambridge, US

Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)Andy Orth(Chief Executive Officer)

Co-investorsAN Venture Partners ARCH Venture Partners Sofinnova Ventures Casdin Capital Fidelity Investments Invus +2 more

Fusion Pharmaceuticalsfusionpharma.com in 𝕏Apr 2019 · $105M

Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.

BiotechHealthtech

Co-investorsFACIT (Fight Against Cancer Innovation Trust)HealthCap Lumira Ventures Pivotal Life Sciences Seroba Life Sciences Venture Ontario +5 more

Homology Medicineshomologymedicines.com inJul 2017

Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.

BiotechBedford, US

Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)

BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)

Co-investors5AM Ventures ARCH Venture Partners OUP (Osage University Partners)Alexandria Deerfield Management Company Fidelity Investments +5 more

Honorhonorcare.com in 𝕏Oct 2021

Honor Technology develops technology platforms and operates brands that provide goods and services for aging adults, aiming to support independent living.

Digital HealthHealthtechLongevitySaaSSan Francisco, US

Cameron Ring(Co-Founder, Honor Technology)inMonica Doss(Co-Founder)Monica Lo(Co-Founder, Honor Technology)in Sandy Jen(Founder)in Seth Sternberg(Founder)in

Co-investorsAndreessen Horowitz Baillie Gifford 8VC BAM Ventures Homebrew Kapor Capital +4 more

Imperativeimperative.com in 𝕏Jul 2021 · $260M

Chronus is a platform that connects employees for guided, AI-assisted conversations focused on career development, mentoring, community building, and change adoption in enterprise organizations.

AI & Machine LearningEnterprise SoftwareFuture of WorkHR TechSaaSNew York, US

Aaron Hurst(Founder)in

Co-investorsVoyager Capital Ally Bridge Group Amed Ventures Ascension Ventures Bain Capital Life Sciences Catalio Capital Management +3 more

MOMA Therapeuticsmomatx.com in 𝕏May 2022 · $150M

A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.

Biotech

Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in

Co-investorsNextech Invest Third Rock Ventures Alexandria Casdin Capital Creacion Ventures Goldman Sachs +3 more

Reneoreneo.de inDec 2020 · $95M

Reneo is an asset and investment management platform for decarbonizing residential real estate portfolios in Germany.

Climate TechEnterprise SoftwarePropTechGermany, DE

Lennart Börner(Founder & Co-CEO)in Alexander Graubner-Müller(Founder & Co-CEO)in

Co-investorsFoundamental Abingworth Aisling Capital Amzak Health Eurazeo Lakestar +4 more

Reneo Pharmaceuticalsreneopharma.comDec 2020 · $95M

Xoilac TV is a free online football (soccer) live-streaming platform serving fans in Vietnam, offering Full HD match broadcasts of European, Asian, Vietnamese, and international competitions.

ConsumerMedia & EntertainmentSports Tech

Co-investorsAisling Capital New Enterprise Associates (NEA)Pappas Capital RiverVest Venture Partners Abingworth Amzak Health +2 more

Seroba Lifesciencesseroba-lifesciences.com inApr 2019 · $105M

This page is a news post from Azafaros, a biopharmaceutical company developing disease-modifying therapeutics for lysosomal storage disorders with a focus on neurological symptoms.

Biotech

Co-investorsCDP Venture Capital Adams Street Partners Genesys Capital HealthCap OrbiMed Pivotal Life Sciences

Simcha Therapeuticssimchatx.com inJan 2022 · $40M

Simcha is a biotechnology company developing new cancer medicines based on immune biology research.

BiotechHealthtechNew Haven, US

Aaron Ring(Executive Officer, Director)in Beatrice McQueen(Chief Operating Officer)inSanuj Ravindran(Chief Executive Officer)Jeremy Barton(Chief Medical Director)Hirdesh Uppal(Senior Vice President Translational Research and Development Sciences)Joseph Catino(Executive Officer)

Co-investorsConnecticut Innovations Pfizer Venture Investments SR One Capital Management Axial VC Biotechnology Value Fund Samsara BioCapital

Synthekinesynthekine.com in 𝕏

Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.

BiotechHealthtech

K. Christopher Garcia(Founder)Susan Molineaux(CEO)inMartin Oft(Chief Scientific Officer)inNaiyer Rizvi(Chief Medical Officer)inGregory(Chief Technical Officer)Geoff(Chief Business Officer)

Co-investorsSamsara BioCapital The Column Group Bain Capital Life Sciences Canaan Partners RA Capital TCG Crossover +2 more

Theseustheseus.us inApr 2021

Theseus builds robotic situational awareness software using visual positioning for drones that operate in GPS-denied environments.

Advanced ManufacturingAI & Machine LearningDefense TechHardwareRoboticsSan Francisco, US

Ian Laffey(Founder)in Sacha Lévy(Founder)in

Co-investorsY Combinator Antler First Round Capital Foresite Capital Longitude Capital Lux Capital +4 more

Theseus Pharmaceuticalstheseusrx.comApr 2021

BiotechCambridge, US

William C. Shakespeare(Director)in

Board Iain Dukes(Executive Officer, Director)in Michael Rome(Director)in Carl Gordon(Director)in

Co-investorsForesite Capital Longitude Capital Nextech Invest NexTech Ventures OrbiMed Pontifax Venture Capital +1 more

Treeline Biosciencestreeline.bioSep 2025

Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.

AI & Machine LearningBiotechHealthtechMedical DevicesWatertown, US

Joshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)in

Board Kristina Burow(Director)inAli Satvat(Director)David Schenkein(Director)in

Co-investorsAisling Capital ARCH Venture Partners GV (Google Ventures)OrbiMed Casdin Capital Fidelity Investments +1 more

Verve Therapeuticsvervetx.comJan 2021

Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.

BiotechCambridge, US

Andrew Ashe(Executive Officer)Sekar Kathiresan(Executive Officer, Director)inAndrew Bellinger(Executive Officer)

BoardJohn Evans(Director)Anthony Philippakis(Director)in Krishna Yeshwant(Director)in

Co-investorsARCH Venture Partners F-Prime Capital GV (Google Ventures)RA Capital venBio Partners Casdin Capital +3 more

Vets First Choicevetsfirstchoice.com inJul 2017 · $223M

Covetrus provides software and pharmacy solutions for veterinary practices, including an integrated platform that manages prescription workflows, online pharmacy storefronts with home delivery, and compounded medication services.

HealthtechMedical DevicesSaaS

Co-investorsHarbor Light Capital Partners Mountain Group Capital Borealis Ventures Clayton Dubilier & Rice HLM Venture Partners Sequoia Heritage +1 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

EIP Pharma Flame Biosciences Menlo Therapeutics Spark Therapeutics

Exits · 8

8 IPOs · showing 7

Avalyn Pharma IncNASDAQ: AVLNBolt BiotherapeuticsNASDAQ: BOLTDisc MedicineNASDAQ: IRONImaraNASDAQ: ELVNImmuneeringNASDAQ: IMRXKorro BioNASDAQ: KRROXilio TherapeuticsNASDAQ: XLO

IPO stake values · per SEC filings · 2

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
Bolt Biotherapeutics	6.4%	$20.00	Feb 2021	$44.1M
Immuneering	4.4%	$15.00	Jul 2021	$16.3M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Frequently asked questions

How many investments has Rock Springs Capital made?: Rock Springs Capital has 29 tracked investments, 8 of which have exited, including 3 dated in the last 24 months.
What stage does Rock Springs Capital invest at?: Rock Springs Capital invests at the Late Stage stage.
What sectors does Rock Springs Capital focus on?: Rock Springs Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Rock Springs Capital located?: Rock Springs Capital is headquartered in Baltimore, US.

Images

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Capricorn Venture Partners

Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.

$270K – $10.8M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.